Valuation : Polaris Group

Market Cap 8.73B 277M 238M 224M 204M 381M 26.25B 383M 2.65B 1.03B 13.42B 1.04B 1.02B 42.7B P/E 2024
-13.6x
P/E 2025 -6.1x
Enterprise Value 9.24B 293M 252M 237M 216M 404M 27.8B 406M 2.81B 1.09B 14.21B 1.1B 1.08B 45.22B EV / Sales 2024
318x
EV / Sales 2025 603x
Free-Float
33.02%
Yield 2024 *
-
Yield 2025 -
1 day-1.46%
1 week-5.14%
Current month-5.14%
1 month-8.56%
3 months-22.81%
6 months-66.83%
Current year-67.36%
1 week 9.99
Extreme 9.99
10.7
1 month 9.99
Extreme 9.99
13
Current year 9.99
Extreme 9.99
35.95
1 year 9.99
Extreme 9.99
39.15
3 years 9.99
Extreme 9.99
87.7
5 years 9.99
Extreme 9.99
232
10 years 9.5
Extreme 9.5
232
Manager TitleAgeSince
Director of Finance/CFO - 28/02/2019
Chief Operating Officer - 31/01/2019
Chief Executive Officer - 30/04/2014
Director TitleAgeSince
Chairman 64 23/11/2014
Director/Board Member - 24/02/2020
Director/Board Member - 02/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
-1.46%-5.14%-73.67%-87.83% 277M
-1.65%-6.17%-3.69%+12.36% 48.01B
-1.29%-1.22%+404.92%+545.45% 44.44B
-3.20%+0.33%+38.11%+21.39% 42.67B
-1.89%-2.00%+1.45%+82.46% 39.96B
-1.72%-2.61%+13.09%+42.33% 32.75B
-0.17%+3.78% - - 17.74B
-0.07%+1.32%+20.08%+117.95% 16.49B
+0.25%-1.92%+11.60%+31.75% 14.38B
-2.68%-0.56%+73.31%+40.56% 13.4B
Average -1.39%-0.86%+53.91%+89.60% 27.01B
Weighted average by Cap. -1.64%-1.05%+84.75%+132.13%

Financials

2024 2025
Net sales 107M 3.39M 2.92M 2.75M 2.51M 4.68M 322M 4.7M 32.53M 12.59M 164M 12.75M 12.47M 523M 40.6M 1.29M 1.11M 1.04M 951K 1.77M 122M 1.78M 12.34M 4.78M 62.41M 4.84M 4.73M 199M
Net income -2.5B -79.39M -68.26M -64.22M -58.61M -109M -7.53B -110M -761M -294M -3.85B -298M -292M -12.24B -3.93B -125M -107M -101M -91.97M -172M -11.81B -173M -1.19B -462M -6.04B -468M -458M -19.21B
Net Debt 9.19M 292K 251K 236K 215K 402K 27.65M 404K 2.79M 1.08M 14.13M 1.1M 1.07M 44.97M 517M 16.4M 14.1M 13.26M 12.1M 22.59M 1.55B 22.71M 157M 60.8M 795M 61.58M 60.23M 2.53B
Logo Polaris Group
The Polaris Group, LLC is a Cayman Islands-based company, which is primarily engaged in biotechnology services, drug testing, contract development and manufacturing services and research, development, manufacture and sales of new drugs. The Company’s core research is ADI-PEG 20, which is undergoing human clinical trials for various cancer indications. The ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, and others. ADI-PEG 20 is a biological drug produced by coupling arginine deiminase and polyethylene glycol with a molecular weight of 20,000.
Employees
-
Date Price Change Volume
08/09/26 NT$10.15 -1.46% 2,022,559
07/09/26 NT$10.30 -0.48% 808,499
04/09/26 NT$10.35 +0.49% 825,107
03/09/26 NT$10.30 -2.83% 1,005,655
02/09/26 NT$10.60 -0.93% 548,603
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. 6550 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!